CTI(SZ:300012)2024-08-15 06:26Financial Performance - In the first half of 2024, Huace achieved revenue of CNY 2.791 billion, a year-on-year increase of 9.20% [1] - Net profit attributable to shareholders reached CNY 437 million, up 1.97% year-on-year; non-recurring net profit was CNY 403 million, an increase of 4.74% [1] - The overall gross margin improved to 49.52% [1] - In Q2 2024, revenue was CNY 1.599 billion, a year-on-year growth of 11.14%; net profit was CNY 304 million, up 7.09% [1] Segment Performance - Life Sciences segment revenue was CNY 1.259 billion, a growth of 21.68% [2] - Industrial Testing segment revenue reached CNY 559 million, increasing by 13.80% [2] - Consumer Products Testing segment revenue was CNY 462 million, a decline of 3.88% [1] - Trade Assurance segment revenue was CNY 375 million, showing stable growth [1] Strategic Developments - Huace is focusing on digital transformation and has expanded its digital services across various sectors, including healthcare, finance, and education [2] - The company is actively pursuing opportunities in the dual carbon and ESG fields, contributing to its growth [5] - Huace has established a comprehensive service capability in the agricultural sector, enhancing its competitive edge [3] Challenges and Outlook - The medical and health services segment faced a decline in revenue, particularly in the pharmaceutical testing area, which is expected to recover in the long term [7] - The company is managing cash flow effectively, with a net cash flow from operating activities of CNY 22.21 million in the first half of 2024 [7] - Huace anticipates stable or improved performance across its product lines in the second half of 2024 [5]